Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

Almirall SA is a global biopharmaceutical company, which is focused on skin health. It engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The firm operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not Allocated Assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological, and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.

Incozen Therapeutics Pvt, Ltd., is headquartered in Hyderabad, India. The company’s primary focus is the development and commercialization of oncotherapies and aims to foster partnerships and collaborations with pharmaceutical companies across the globe. Led by a team of experienced individuals, the company aims to leverage its combined strength in preclinical discovery, formulation development, and clinical research to become a major player in the oncology space. With a team of top notch scientists equipped with years of experience in cancer research spread across preclinical discovery, formulation development, and clinical research, Incozen hopes to come up with exciting therapeutic options for potential clinical evaluation in regions across Asia, Europe, and Australia. Incozen’s affiliate, Rhizen Pharmaceuticals SA, is located in Switzerland with an associate arm in the USA and manages business development outreach and licensing for the North American and European markets Incozen is an affiliate company of Alembic Pharmaceuticals Ltd, one of India’s oldest and leading multi-national publicly-listed conglomerate with businesses across pharmaceuticals, glass, chemicals, real estate, engineering, education and healthcare domains. Alembic’s pharmaceutical business has a global footprint (both operations and commercial); capabilities spanning API, generics & specialty products and a proven track record of regulatory and commercial success across all the major markets. Incozen, Rhizen, and Alembic’s shared vision and common representation at the board and investor level, has allowed optimal alignment of their strategy and operations for maximal mutual benefit.

Rhizen Pharmaceuticals AG is a private company headquartered in La Chaux-de-Fonds, Switzerland. The firm develops pharmaceutical products. It was founded by Swaroop Vakkalanka, who is currently the CEO of the company.\nThe company says this about itself: Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen has proven expertise in the PI3K modulator space with the discovery of our first PI3Kd & CK1e asset Umbralisib, that has been successfully developed & commercialized in MZL & FL by our licensing partner TG Therapeutics (TGTX) in USA. Rhizen is also developing Tenalisib, a unique dual PI3K-d/? & SIK3 inhibitor with a robust safety profile and promising activity in metastatic breast cancer and T-Cell lymphoma indications. Behind these assets, Rhizen has a deep oncology & inflammation pipeline spanning discovery to clinical development stages. Rhizen is headquartered in Basel, Switzerland.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Manufactures pharmaceuticals

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Axaron Bioscience AG is a German private company located in Heidelberg with domestic subsidiaries. The firm develops biotechnologies.

4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. Its product pipeline includes resminostat and domatinostat. The company was founded by Stefan Busemann, Ulrich Dauer, Klaus-Peter Gulden, and Daniel Vitt in 1997 and is headquartered in Planegg-Martinsried, Germany.

Develops and manufactures agricultural and noncrop products

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria. The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications. Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development.

Merck Serono S.A. discovers, develops, manufactures, and commercializes prescription medicines focusing on various therapeutic areas that include oncology, immuno-oncology, immunology, multiple sclerosis, fertility, endocrinology, biosimilars, and neglected diseases. It develop treatments to help manage neurodegenerative diseases, such as multiple sclerosis; colorectal cancer; drugs to treat head and neck cancer; fertility drugs for every stage of the reproductive cycle.